Need to keep on prime of the science and politics driving biotech right now? Join to get our biotech publication in your inbox.
Merck’s wager on an antibody-drug conjugate developed in China has paid off in a significant Part 3 lung most cancers examine, the place sacituzumab tirumotecan paired with Keytruda sharply outperformed Keytruda alone in a subset of lung most cancers sufferers.
Additionally, the NIH is down one other chief, and Sam Altman-backed longevity startup Retro Biosciences raises extra funds.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans
